|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.23 EUR | -0.33% |
|
+0.55% | -7.85% |
| 07-10 | Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector | CI |
| 07-10 | Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 105B | |||||
| 1,060B | |||||
| 619B | |||||
| 438B | |||||
| 333B | |||||
| 282B |
- Stock Market
- Stocks
- SAN Stock
- Charts Sanofi
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
